ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	298.67	150.39	163.37	37.28
Cash & Short-Term Investments	298.67	150.39	163.37	37.28
Cash Growth	63.36%	-7.95%	338.23%	-
Other Receivables	0.75	0.76	0.5	0.25
Receivables	0.75	0.76	0.5	0.25
Prepaid Expenses	1.23	0.37	0.33	0.03
Other Current Assets	7.87	8.45	18.42	5.39
Total Current Assets	308.51	159.97	182.62	42.95
Property, Plant & Equipment	0.22	0.29	0.14	-
Long-Term Deferred Charges	-	2.73	-	-
Other Long-Term Assets	0.13	0.11	0.07	0.09
Total Assets	308.86	163.1	182.83	43.04
Accounts Payable	3.81	4.53	3.09	0.29
Accrued Expenses	8.13	6.95	5.14	1.53
Current Portion of Leases	0.15	0.14	0.13	-
Total Current Liabilities	12.1	11.62	8.36	1.82
Long-Term Leases	0.1	0.18	0.01	-
Total Liabilities	12.2	11.8	8.37	1.82
Additional Paid-In Capital	493.79	4.65	3.4	2.96
Retained Earnings	-197.14	-157.85	-88.51	-51.61
Comprehensive Income & Other	-	-	-	-0
Total Common Equity	296.66	-153.19	-85.11	-48.64
Shareholders' Equity	296.66	151.3	174.46	41.22
Total Liabilities & Equity	308.86	163.1	182.83	43.04
Total Debt	0.25	0.32	0.14	-
Net Cash (Debt)	298.42	150.07	163.23	37.28
Net Cash Growth	63.29%	-8.06%	337.86%	-
Net Cash Per Share	18.70	70.10	127.82	52.42
Filing Date Shares Outstanding	33.59	33.49	31.96	0.71
Total Common Shares Outstanding	33.51	2.75	2.6	0.71
Working Capital	296.41	148.34	174.26	41.13
Book Value Per Share	8.85	-55.80	-32.76	-68.40
Tangible Book Value	296.66	-153.19	-85.11	-48.64
Tangible Book Value Per Share	8.85	-55.80	-32.76	-68.40

Source: S&P Capital IQ. Standard template. Financial Sources.